Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization

被引:44
作者
Introini, U. [1 ]
Casalino, G. [1 ]
Querques, G. [1 ]
Gimeno, A. T. [1 ]
Scotti, F. [1 ]
Bandello, F. [1 ]
机构
[1] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Ophthalmol, I-20132 Milan, Italy
关键词
spectral-domain OCT; pathologic myopia; choroidal neovascularization; anti-VEGF; INTRAVITREAL RANIBIZUMAB; PATHOLOGICAL MYOPIA; MACULAR DEGENERATION; PHOTORECEPTOR LAYER; DOSING REGIMEN; BEVACIZUMAB; THERAPY; VERTEPORFIN; FEATURES;
D O I
10.1038/eye.2012.75
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To evaluate changes in macular morphology due to myopic choroidal neovascularization (CNV), using spectral-domain optical coherence tomography (SD-OCT). Methods In all, 22 eyes with recent-onset untreated CNV underwent 1 intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF), followed by a pro-re-nata regimen. SD-OCT was performed at baseline (before first administration of anti-VEGF treatment) and month 1, and 2; macular morphologic changes and outer retina characteristics (SD-OCT findings) associated with CNV activity were evaluated. Sensitivity and specificity were calculated for SD-OCT findings using fluorescein angiography (FA) as standard reference. Results Mean central retinal thickness (CRT) showed no significant reduction from baseline (284 +/- 98 mu m) to month 1 (257 +/- 74 mu m) and month 2 (263 +/- 72 mu m). A hyper-reflective lesion with fuzzy borders (fuzzy area), and 'absent or altered' IS/OS junction were the only SD-OCT findings associated with CNV activity (P<0.0001). Both these SD-OCT findings showed good sensitivity and specificity (95.1 and 96.0% (95% CI: 0.87-0.89), respectively, for the fuzzy area; 87.9 and 66.7% (95% CI: 0.65-0.87), respectively, for 'absent or altered' IS/OS junction) when compared with FA leakage (standard reference). Conclusions Outer retina characteristics (ie, hyper-reflective lesion with fuzzy borders, and 'absent or altered' IS/OS junction) appear more meaningful than CRT in the evaluation of myopic CNV activity. These SD-OCT findings show overall good sensitivity and specificity when compared with FA leakage (standard reference), and could be considered as an alternative diagnostic tool to FA for myopic CNV monitoring. Eye (2012) 26, 976-982; doi:10.1038/eye.2012.75; published online 27 April 2012
引用
收藏
页码:976 / 982
页数:7
相关论文
共 23 条
[1]  
AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
[2]   Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia - 2-year results of a randomized clinical Trial - VIP report no. 3 [J].
Blinder, KJ ;
Blumenkranz, MS ;
Bressler, NM ;
Bressler, SB ;
Donati, G ;
Lewis, H ;
Lim, JI ;
Menchini, U ;
Miller, JW ;
Mones, JM ;
Potter, MJ ;
Pournaras, C ;
Reaves, A ;
Rosenfeld, P ;
Schachat, AP ;
Schmidt-Erfurth, U ;
Sickenberg, M ;
Singerman, LJ ;
Slakter, J ;
Strong, HA ;
Virgili, G ;
Williams, GA .
OPHTHALMOLOGY, 2003, 110 (04) :667-673
[3]   Ranibizumab versus verteporfin for neovascular age-related macular degeneration [J].
Brown, David M. ;
Kaiser, Peter K. ;
Michels, Mark ;
Soubrane, Gisele ;
Heier, Jeffrey S. ;
Kim, Robert Y. ;
Sy, Judy P. ;
Schneider, Susan .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1432-1444
[4]   Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization - Six-month results of a prospective pilot study [J].
Chan, Wai-Man ;
Lai, Timothy Y. Y. ;
Liu, David T. L. ;
Lam, Dennis S. C. .
OPHTHALMOLOGY, 2007, 114 (12) :2190-2196
[5]   ANTI-VEGF DRUGS AS THE 2009 FIRST-LINE THERAPY FOR CHOROIDAL NEOVASCULARIZATION IN PATHOLOGIC MYOPIA [J].
Cohen, Salomon Y. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2009, 29 (08) :1062-1066
[6]   An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration [J].
Fung, Anne E. ;
Lalwani, Geeta A. ;
Rosenfeld, Philip J. ;
Dubovy, Sander R. ;
Michels, Stephan ;
Feuer, William J. ;
Puliafito, Carmen A. ;
Davis, Janet L. ;
Flynn, Harry W., Jr. ;
Esquiabro, Maria .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2007, 143 (04) :566-583
[7]   Intravitreal Bevacizumab Treatment for Choroidal Neovascularization in Pathologic Myopia: 12-month Results [J].
Gharbiya, Magda ;
Allievi, Francesca ;
Mazzeo, Luigi ;
Gabrieli, Corrado Balacco .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 147 (01) :84-93
[8]  
HAMPTON GR, 1983, OPHTHALMOLOGY, V90, P923
[9]   Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study [J].
Holz, Frank G. ;
Amoaku, Winfried ;
Donate, Juan ;
Guymer, Robyn H. ;
Kellner, Ulrich ;
Schlingemann, Reinier O. ;
Weichselberger, Andreas ;
Staurenghi, Giovanni .
OPHTHALMOLOGY, 2011, 118 (04) :663-671
[10]   Spectral-domain optical coherence tomography images of inner/outer segment junctions and macular hole surgery outcomes [J].
Inoue, Maiko ;
Watanabe, Yoichiro ;
Arakawa, Akira ;
Sato, Shimpei ;
Kobayashi, Satoshi ;
Kadonosono, Kazuaki .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2009, 247 (03) :325-330